Fundación Ramón Areces , profile picture
Uploaded byFundación Ramón Areces
627 views

María Blasco-Investigar, educar, dialogar

The Spanish National Cancer Research Centre (CNIO) was established in the late 1990s to enhance Spain's research capabilities in cancer, operating under the Ministry of Economy with a focus on scientific excellence. CNIO's organizational structure supports independence in funding and research management, fostering an international environment for collaboration and innovation, including drug discovery initiatives. The Centre has reported significant advancements in clinical research, scientific publications, and public engagement, emphasizing its role in translating basic research into clinical applications.

Science◦
Related topics:
Unión Europea•

Embed presentation

Spanish National Cancer Research Centre (CNIO) Going beyond “excellence”
A bit of history…  The Spanish National Cancer Research Centre (CNIO) was conceived by the Spanish Government at the end of the 90’s as a part of a long term Strategic Plan to endow Spain with a series of excellence research centres (CNIO, CNIC, etc)  CNIO is managed by a Public Foundation currently belonging to the Spanish Ministry of Economy and Competitivity (MINECO)  The CNIO has independence to manage its funds and human resources under a criterium of scientific excellence (External Scientific Advisory Board)  CNIO personnel enjoys work contracts identical to those of the employees of private companies  CNIO has control of its budget, including funds provided by the Ministry  The CNIO Director reports directly to the Board of Trustees, presided by the Secretary of State for Research, currently Ms. Carmen Vela  Main features of CNIO’s administrative system include:
CNIO External Advisory Board (2016) Mariann Bienz (Chair) Medical Research Council, Cambridge, UK Joan Massagué Memorial Sloan Kettering Cancer Center, New York, USA Angela Nieto Instituto de Neurociencias, Alicante, Spain Lauri Altoonen Biomedicum, Univ. of Helsinski, Finland Genevieve Almouzni Institute Curie, Paris, France Sara Courtneidge Oregon Health & Science University, Portland, USA John Diffley CRUK London Research Institute, Hertfordshire, UK Denise Galloway Fred Hutchinson Cancer Research Center, Seattle, USA Scott Lowe Memorial Sloan Kettering Cancer Center, New York, USA Janet Thornton European Bioinformatics Institute, Hinxton, UK Michael Bishop Hooper Research Foundation, San Francisco, USA Ada Jonah Weizmann Institute of Science, Rehovot, Israel José Costa Yale Comprehensive Cancer Center, New Haven, USA Karen Vousden The Beatson Institute for Cancer Research, Glasgow, UK Alfred Wittinghofer Max Plank Institute for Molecular Physiology, Dortmund, Germany Josep Tabernero Director Oncology Institute, Vall d’Hebron Hospital, Barcelona, Spain
14% non-spanish Group Leaders Staff Scientists Lab techs 22% non-spanish 11% non-spanish Post-doctorals PhD students 49% non-spanish 41% non-spanish International Environment
Italy Germany Portugal USA France Austria Serbia UK Poland Greece Romania Mexico Ireland India Cuba Croatia Venezuela Ukraine Turkey Switzerland Sweden Slovenia Russia ebanon Israel Hungary Colombia Ciprus China Czech Republic Bulgaria Argentina International research environment (countries)
Research Organization (2016) Basic Research Cancer Cell Biology 4 Research Groups: 2 senior + 3 junior Molecular Oncology 10 Research Groups: 7 senior + 3 new Junior Groups in 2016 Structural Biology and Biocomputing 3 Research Groups: 1 senior + 2 junior 3 Support Units + 1 new Unit on Text Mining in 2016 E. WAGNER M. SERRANO A. VALENCIA (Vice-Director)
Translational Research Human Cancer Genetics 4 Research Groups: 4 senior 2 Support Units Clinical Research (CNIO-Hospitals) 3 Clinical Research Units: 1 senior + 2 junior 2 Support Units 2 new CNIO-H12O Clinical Research Units in 2015 Biotechnology 8 Support Units Experimental Therapeutics 2 sections (Biology & Chemistry) 2 Eli-Lilly labs Technology Transfer J. BENITEZ M. HIDALGO (Vice-Director hasta Dec 2015) O. FERNANDEZ-CAPETILLO (Vice-Director Director de Innovación) F. PELAEZ J. PASTOR Research Organization II (2016) A. SANZ
CNIO Excellence (rankings, papers, etc) Spanish National Cancer Research Centre (CNIO)
Total number of publications 0 50 100 150 200 250 300 Totalnumberofscientificpublications Senior author from CNIO CNIO co-authorship
0 10 20 30 40 50 60 70 Totalnumberofhighqualitypublications Impact factor >15 Impact factor 10-15 Excellence: “top papers”
International Ranking 2015 (cancer centers) (out of 4840 institutions (99 Spain) Scimago July 2010-2015) Excellence with Leadership CNIO Position in the International Ranking Cancer Centers Rank Cancer Research Centers Country Ewl %Ewl: Excelence with Leadership: The amount (in %) of an institution’s scientific output that is included into the set of the 10% of the most cited papers in their respective scientific fields in which the institution is the main contributor. This is a size- independent indicator.
Parameter Q1 International Ranking 2015 (cancer centers) (out of 4840 institutions (99 Spain) Scimago July 2010-2015) CNIO Position in the International Ranking Cancer Centers Rank Cancer Research Centers Country Q1 Q1: High Quality Publications: Ratio of publications that an institution publishes in the most influential scholarly journals of the world, those ranked in the first quartile (25%) in their categories as ordered by SCImago Journal Rank (SJRII) indicator. This is a size-independent indicator.
Scientific productivity according to Nature Index AC: Total number of papers from June 1st, 2014, to May 31st, 2015 FC: Fractional count (considering the % of CNIO authors and number of institutions in each paper) WFC: Weighted fractional count in which some fields of physics is down weighted Nature Index tracks data from the publications issued in a selection of 68 high quality journals compiled by the Nature Publishing Group in collaboration with Digital Science
Ranking of Spanish institutions according to Nature Index The table includes top Spanish institutions in the field of life sciences, ranked by their FC
Spanish Healthcare Institutions Nature Index
Associated Hospitals Oncologists on board Spanish National Cancer Research Centre (CNIO)
Red de Ensayos Clínicos CNIO 2015 Clinical Trial Network (collaborations ad hoc) Associated Clinical Units # Hospital HM - Hospital de Madrid (since 2008) # Hospital Fuenlabrada (since 2009) # Hospital Ramón y Cajal (since 2012) # Hospital La Paz (since 2012) # Fundación Jiménez Díaz (since 2012) # Hospital Niño Jesús (since 2013) # Hosp. Regional y Virgen de la Victoria Málaga (since 2014) # Hospital 12 de Octubre (since 2015) # Hospital Clínico San Carlos (since 2015) # Hospital Quirón (since 2016) M. HIDALGO Programme Director CNIO M.A. QUINTELA (CNIO) D. OLMOS (CNIO) L. MORENO (CNIO) J. MARTÍNEZ (CNIO-H12O) L. PAZ-ARES (CNIO-H12O)
Personalized cancer treatment platform Human tumour implant in mice (xenograft) ‘AVATAR’ mice Bioinformatic Analysis Data handling & integration Testing of candidate drugs in Avatar mice Therapeutic decision (personalised treatment) Datacollection # Molecular data # Clinical data # Biological data # Pharmacol. data # Epidemiologic data # Databases & Publ. Extraction of clinically ‘useful’ information
Hidalgo et al, Can Dis 2014 Avatars recapitulate the patient´s tumor
NGS: next generation sequencing positive: genetic councelling negative: more research candidates for NGS new genes We discover new familial cancer genes
We read all exome Rapid translation of results
CNIO-Innovation: Drug discovery, partnering, lisencing… Spanish National Cancer Research Centre (CNIO)
Drug development at CNIO Joaquin Pastor, Director of Experimental Therapeutics Program at CNIO
Drug discovery at CNIO: Our mission “Our mission is to serve as a bridge between basic research and potential therapeutic applications through the discovery and development of innovative drug candidates for clinical development”
VIB: Model for External Collaborations Currently under CNIO Internal development Drug discovery at CNIO: Our pipeline
Development of ATR inhibitors IN COLLABORATION WITH EXPERIMENTAL THERAPEUTICS PROGRAM O. F-CAPETILLO
10 Gy + ATRi mM ATMp Chk1p TOLEDO ET AL NSMB (2011) Clinical Trials 2016 2013 ETP CNIO Development of ATR inhibitors Income millestones 2013- 2015: 900.000 euros Next millestone: 1.500.000 euros
4 Spanish Centers are registered… “ETP-CNIO” is Unique in Spanish Public Research Institutions meeting the criteria of “pharma”/academic experience, integrated capabilities and a proven record of achievements in academic drug discovery. Drug discovery at CNIO: part of a network
Income from partnering  2015: Significant increase ( 2 X ) in the number of industrial collaborators (from 10 to 20) . (new agreements wit Boehringer Ingelheim, Merck KaaG, Daiichi Sankyo…) Significant increase in funding for fundamental research projects ( preclinical research)  4.5 M. € secured for collaborative research Significant increase in funding for fundamental research projects ( preclinical ) 1.425773 1.706681 2.675406 2.535579 4.715486 4.48672988 0 0.5 1 1.5 2 2.5 3 3.5 4 4.5 5 2010 2011 2012 2013 2014 2015 (Dic) Millions Collaborative Research with partnering
Roche: Expanding Innovation Networks
CNIO Royalties – commercialization -  CNIO Intelectual Property Portfolio  60 patents (2007-2015)  14 (23%) have been licenced  In 2015, 1 new priority patent application (ETP)  24 commertial reagents (antibodies & chemical compounds)  2014 commertialization  25 technologies in exploitation: 24 marketed; 1 (ATRi) in development  Net royalty (2014): 780.840 €  Income from royalties contributes to the sostenability of the centre, to support research in the research groups that generate the invention and to recognize the Inventors. Spin Offs Chemical Matter Biological Material
CNIO Inventors (>10% of CNIO personnel)  CNIO is commited to recognize its Inventors, thorugh a royalty distribution policy  More than 40 scientist have contributed to the development of the commertialized technologies. (aprox. 10% of CNIO personnel).  CNIO Inventors belong to all scientific programs. Molecular Oncology, Biotechnology and Experimental Therapeutic being the main contributors. 1 2 3 Inventors Research Groups CNIO Institution Inventors per Scientific Programme Royalty Distribution
Training researches in management and bussines administration In collaboration with IE business School  23 CNIO scientist have followed the training  Building skills & attitudes, Expanding CNIO Network. Fostering Innovation Culture
Update training & conferences PhDs, postdocs, seminars, meetings…. Spanish National Cancer Research Centre (CNIO)
Dean´s Office
Training Programs (2014-2015) PhD Fellowships associated to Severo Ochoa Program “La Caixa” – Severo Ochoa International PhD Program Posdoctoral Program for scientists from UK or USA (Banco Santander Foundation) Training Program on Molecular Pathology for medical residents Training Program on Familial Cancer for MIR, BIR and FIR CNIO Onco-MIR Rotation Program for MIR residents (Celgene) CNInnOtrain Program IE Business School (Banco Santander Foundation) Laboratory Training Program for Undergraduate and Postgraduate Students Training Program for Vocational Students (Laboratory Technicians) Master in Therapeutical Targets, Research and Development (Alcalá de Henares University) Diploma on Translational Research applied to Personalized Oncology. Master in Clinical Research Applied to Oncology (San Pablo-CEU University) Master in Molecular Oncology (Centro de Estudios Biosanitarios) Postgraduate Program in Biochemistry, Molecular Biology, Biomedicine and Biotechnology (Autónoma University of Madrid) Program for visiting scientists at CNIO (Jesus Serra Foundation)
Distinguished Seminars by Oncology Leaders
Distinguished Seminars with the French Embassy Shahragim Tajbakhsh Instituto Pasteur 7 Noviembre 2014 Jean-Pierre Changeux Instituto Pasteur Paris, France 4 Noviembre 2014 Emmanuel Barillot Instituto Curie 13 Junio 2014
We organize international conferences  CNIO Frontiers Meetings (2-3 year)  Nature-CNIO Symposia (2007, 2010, 2013)  Co-organizing with International Associations (p.ej. ESO)
2016 Canceromatics III: Tumour heterogeneity Organizers: Fatima Al-Shahrour (CNIO, Madrid) Núria Malats (CNIO, Madrid) Alfonso Valencia (CNIO, Madrid) Chris Sander (MSKCC,USA) Proposed date: 13-16 Nov, 27-30 2017 Molecular Chaperones in Cancer Organizers: Nabil Djouder (CNIO, Madrid) Wilhelm Krek (ETH, Zurich) Paul Workman (ICR, London) Helena Yang (Cancer Cell Editor) Date: 2-4 May Malignancies in the Central Nervous System: Unknown Biologies towards Therapeutic Applications Organizers: Manuel Valiente (CNIO, Madrid) Massimo Squatrito (CNIO, Madrid) Richard Gilbertson (Cancer Research UK Cambridge Centre) Lisa Hutchinson(Nature Reviews Clinical Oncology Editor) Date: 19-21 Oct CNIO Frontiers Meetings 2016 and 2017
Patrick Sung Yale University School of Medicine, USA (Chromosome Dynamics Group) Chaitanya R. Divgi Columbia University, NY Presbyterian Hospital, USA (Seve-Ballesteros Foundation Brain Tumour Group ) Marcin Nowotny International Institute of Molecular and Cell Biology, Poland (Structural Bases of Genome Integrity Group ) Sabaticals “Jesús Serra” 2015
New logo Women in Science @ CNIO Office
Seminars of the Women in Science (WISE) office 2016 María Teresa Fernández de la Vega. President Fundación Mujeres por Africa, Madrid, Spain Edurne Pasaban. Mountaineer, Tolosa, Spain In Her Own Voice: MIT's Earliest Women Scientists. Margery Resnick. Massachusetts Institute of Technology, Cambridge, US and International Institute in Madrid, Spain Woman and Technology: a positive story. María Concepción Ferreras. You Tube, Head of Partnerships, Southern Europe and Russia 2015 Women in Business and Science : two parallel paths. Natalia González- Valdés. Corporate Communications and CSR (Corporate Social Responsibility) Director of L'Oreal Spain Women at the top: Making it happen. María del Mar Martínez. Director at McKinsey's Madrid Office, Spain My life with phage ø29. Margarita Salas Falgueras. CBMSO, Madrid, Spain A professional career with a gender perspective. Maria Carmen Vela Olmo. Secretariat of State of Research, Development and Innovation, Ministry of Economy and Competitiveness, Madrid, Spain Sex, Science and Society: a triangle that matters? Flora de Pablo. CSIC, Madrid, Spain 10/05 08/03 19/01 12/01 24/11 09/06 14/04 10/03 17/02
Communication & outreach: News papers, TV, social networks… Spanish National Cancer Research Centre (CNIO)
Communication CNIO appearances in printed & digital media (up to 30th November 2015) 0 500 1000 1500 2000 2500 3000 Jan-Mar Apr-Jun Jul-Sep Oct-Dec Total 89 118 87 98 392 98 250 220 193 761 195 378 342 438 1353 387 547 603 760 2297 587 629 685 624 2525 2011 2012 2013 2014 2015 (up to 30 Nov)
International presence of CNIO press releases (from March 2012 to 30th November 2015) Press Releases Published: 110 Total visits: 308,514 Communication Average/PR: 2,805 Average/month: 6,855 Top 15 Press Releases
Communication TV and radio broadcasts [Colombia]
Communication Highlighted appearances in printed & digital media
Communication CNIO news released in front pages
Public engagement - Events Science’s Week Initiative organised by Madri+d. The attendants learned more about the CNIO facilities, enjoyed a guided tour in some of the laboratories and talked with our researchers about the scientific career and the work In the Centre. Attendants: 50 people European Researchers’ Night Activity organised by Madri+d. Children and adults had the opportunity to learn more on the CNIO cancer research. They also extracted DNA from a tomato and took part in a ‘speed dating’ session with the 40 young researchers who participated in the activity. Attendants: 200 people 25/09/2015 05/11/2015
www.cnio.es Engaging society
Launched in February 2015 for the initiative “CNIO Friends” Communication From February 15, 2015, to May 12, 2016: 31,026 followers Reach: 50,767.231 users * 239,664 ‘likes’ 16,676 comments 66,555 shares * Number of people who received contents from the page Interaction: 73% * * Number of interactions per followers
Internet Day Award – Best Facebook Page 2016 Communication
Shown and aired in:CNIO Friends appearances: Print and digital media: 87 Radio: 18 TV: 13 Video “Become a Friend of CNIO” Total views in Youtube: 22,844 Video by Amparo Garrido
0 € 10.000 € 20.000 € 30.000 € 40.000 € 50.000 € 60.000 € 70.000 € 80.000 € 90.000 € 100.000 € 2011 2012 2013 2104 2015 2016 Donations CNIO Friends Donations before the launch of CNIO Friends Evolution of donations at CNIO * * The initiative “CNIO Friends” was launched in November 2014 (until May 23)
CNIO Friends (May 23, 2016): 657 donors 598 8 Sponsors Benefactors Friends 51
Amigos del CNIO: primera empresa Patrocinadora
New CNIO Friends + Research on children’s cancers Recreational areas in hospitals for children with cancer
• ERC Bridge: An endowment based on the legacy from D. Miguel Martín (ca. 400,000€) to support the Groups of Excellence of the CNIO  Other legacies can be added in the future • Goal: to provide financial support to Groups in the the process of renewing their ERC Grants. • Eligibility criteria: Groups holding an ERC Grant (Starting, Consolidator or Advanced), which apply again but do not get the new one right after • Procedure:  Groups will place a request to CNIO for this support, indicating the amount requested and intended destination of the funds  Maximum amount granted: 100,000€ for Senior Groups; 50,000€ for Junior Groups  Maximum time: 1 year o The amount would be reduced proportionally if the renewal of the grant is obtained before the end of this 1-year period. Creation of the “ERC Bridge Endowment”
“Constantes y Vitales”: La Sexta + Fundación AXA  >6,000 participants; 650,000 Km  100,000 euros to fund the research of the Microenvironment and Metastasis Group (Héctor Peinado) at CNIO  Challenge: to turn Kms into one year of cancer research
0 € 50.000 € 100.000 € 150.000 € 200.000 € 250.000 € 300.000 € 350.000 € 400.000 € 2011 2012 2013 2104 2015 2016 Donations before the launch of CNIO Friends Donations CNIO Friends ATRESMEDIA Legacies Evolution of donations at CNIO * (until May 23) * The initiative “CNIO Friends” was launched in November 2014
CNIO Friends Fund CNIO FRIENDS POSTDOCTORAL FELLOWSHIPS Duration: 2 years Starting 2016
Our view of the CNIO Research Innovation Solutions $ Training Communication Phylantropy $ Education WIS E WIS E Dean´s Offic e CNI O Personnel Unions
Negotiation of the Collective Agreement Excerpt of the Agreement signed by the Fundación CNIO Carlos III with the Works Council on December 20, 2013: “…..it is agreed to initiate the negotiations on the 1st of February of 2014 to ellaborate a Collective Agreement for all the workers of the Centre”. Negotiating Table Activities 2014 - A first draft of the Collective Agreement is elaborated for discussion Activities 2015 - January 21: kick off of the negotiation and discussions on the draft - July 27: after 18 meetings between the parties, a first agreed version is reached that is communicated to all the employees - Sept-Nov: last changes are incorporated to present a final version to the meeting of the Board of Trustees in December Agreements already reached - June 23: The Board of Trustees approves the application of the new timetable based on 37.5 hours per week in an unbroken day schedule (Art. 24) - July 24: The application of the new policy on the compensation of extra hours beyond the regular time schedule is approved (Art. 25) - October 28: The Comisión Delegada approves the consideration of the 24th and 31st of December as non-working days (Art. 27) Director Managing Director Dir. Biotechnology Programme Dir. Experimental Therapeutics Prog. Dir. Administration and Finances Dir. Personnel Chair of the Works Council 5 members representing the different sections of the Council: 2 members of CCOO 2 members of UGT 1 member of “Integrando CNIO” On behalf of the CNIO On behalf of the Works Council
Our view of the CNIO Research Innovation Solutions $ WIS E WIS E Dean´s Offic e CNI O Personnel Unions Training Communication Phylantropy $ Education
Spanish National Cancer Research Centre (CNIO) After substantial operative deficit during (2009-2012),CNIO accounts are now balanced: 2012: -4.849.000 € 2013: +1.016.000 € 2014: +488.000 € 2015: +100.000 € 2016: aprox. +100.000 € (estimation) We are, however, returning the ETP loans (2009-2011) to the Government (~4 M € per year) and this represents a stress to our savings
Looking ahead: CNIO 2015-2018 Spanish National Cancer Research Centre (CNIO)
Spanish National Cancer Research Centre (CNIO) Groups 2015-2018 Five Junior Groups (Pérez-Moreno, Djouder, Quintela, Ramón-Maiques, and Lietha) will finish their 5+3 stay at the CNIO. Two Junior Groups (Squatrito and Olmos) will have their 5- year evaluation for a 3-extension at CNIO). Three new Junior Groups (Peinado, Valiente, Efeyan) would be at their mid-term period at CNIO. Recruitment of new Groups (Structural Biology; Immune System; Microbiota…others?).
Spanish National Cancer Research Centre (CNIO) Challenges Renew the Severo Ochoa Excellence Acreditation (2016- 2020) (1 million €). Increase public funding (Government + Competitive). Increase contracts with Industry (ETP + Groups). Increase institutional and individual phylantropy. Recover flexibility: hiring, salaries (productivity)….
Highlighted appearances in printed & digital media Communication
Communication Social media Launched in June 2009 70 videos 172 subscribers Total views: 35,963
10 Gy + ATRi mM ATMp Chk1p Development of ATR inhibitors TOLEDO ET AL NSMB (2011) Sent to > 70 laboratories around the world We provided the Synthesis protocol as Supp Information Towards the Clinic TOLEDO ET AL NAT STRUCT MOL BIOL (2008) 2013 ETP CNIO Income 2013-2015: 900.000 euros
CNIO-Merck license agreement
Carbo/PEM + Demcizumab Ph1b FL-NSCLC (IIIB/ IV) • Carbo: AUC 6 Q3W x 6 • PEM: 500 mg/m2 Q3W x 6 • DEM: 2.5, 5mg/kg Q3W and 7.5mg/kg Q3W x4 Demcizumab: inhibidor de Notch en NSCLC fase 1
Demcizumab: First-Line NSCLC Study RECIST Waterfall Plot Partial Response 9/28 (39%) Stable Disease 1/28 (48%) Progress Dis. 3/28 (13%)
Collaborations with Big Pharma (Roche) 3 projects funded (2013- 2015) A total of 520.000 euros
H12O-CNIO Clinical Research Units since 2015 Joaquín Martínez Luís Paz-Ares
Tumor detection by PET/CT 15 days after detection No treatment Mouse with a lung tumor Untreated mouse Mouse with a lung tumor Treated with Notch inhibitor Tumor detection by PET/CT 15 days After treatment Accelerate translation from basic research to patients Notch: A new target for lung and pancreas cancer Clinical Trial with anti-Notch in pancreas And lung cancer (ONCOMED Anti-DLL4) Maraver et al. Cancer Cell, 2012 Manuel Serrano Tumor Suppression Group CNIO
Pre-treatment (03/27/2012) Post-treatment (04/27/2012) Anti-DDL4 (Oncomed Clinical Trial) Anti-DDL4 ? Discovery of new drug combinations
0 10 20 30 40 0 200 400 600 800 1000 1200 1400 Control mAb Gemcitabine (30 mg/kg) Gem (10 mg/kg) +Abrx (30 mg/kg) Anti-DLL4 + Gem Anti-DLL4 + Gem/Abrx Days Post Treatment TumorVolume,mm3 • Patient progressed on treatment, day 11 (anti-DLL4, 2.5 mg/kg q4w + gemcitabine) • Patient derived tumor shows increased sensitivity to gem/Abraxane vs. gem alone • Combination activity observed with anti-DLL4 + gem/Abraxane, but not with anti-DLL4 + gem 0 10 20 30 40 0 100 200 300 Gem (10 mg/kg) +Abrx (30 mg/kg) Anti-DLL4 + Gem/Abrx Anti-DLL4/VEGF + Gem/Abrx Days Post Treatment TumorVolume,mm3Gem/Abraxane vs. Gem/Abrx + Anti-DLL4; P = 0.04 Discovery of new drug combinations
-100 -90 -80 -70 -60 -50 -40 -30 -20 -10 0 10 Gemcitabine-NabPTX-Dencizumab Discovery of new drug combinations (pancreas)
María Blasco-Investigar, educar, dialogar
María Blasco-Investigar, educar, dialogar
María Blasco-Investigar, educar, dialogar
María Blasco-Investigar, educar, dialogar
María Blasco-Investigar, educar, dialogar
María Blasco-Investigar, educar, dialogar
María Blasco-Investigar, educar, dialogar

More Related Content

PPTX
What to Upload to SlideShare
bySlideshare
 
PDF
Getting Started With SlideShare
bySlideshare
 
PPTX
Cristina Gallardo-La carrera investigadora en Reiino Unido
byFundación Ramón Areces
 
PPTX
Francisco Guinea-Recent advances in graphene research
byFundación Ramón Areces
 
PDF
Everyone Gains When You Go Beyond Borders
byRotary International
 
PPTX
Tomás Palacios-Redefining electronics
byFundación Ramón Areces
 
PDF
CNIO Frontiers Meeting New Trends in Anticancer Drug Development March 22‐25,...
byDr. Aurora Bakaj
 
PPTX
10 years of biosimilars who benefits (1)
byLuis Sales
 
What to Upload to SlideShare
bySlideshare
 
Getting Started With SlideShare
bySlideshare
 
Cristina Gallardo-La carrera investigadora en Reiino Unido
byFundación Ramón Areces
 
Francisco Guinea-Recent advances in graphene research
byFundación Ramón Areces
 
Everyone Gains When You Go Beyond Borders
byRotary International
 
Tomás Palacios-Redefining electronics
byFundación Ramón Areces
 
CNIO Frontiers Meeting New Trends in Anticancer Drug Development March 22‐25,...
byDr. Aurora Bakaj
 
10 years of biosimilars who benefits (1)
byLuis Sales
 

Similar to María Blasco-Investigar, educar, dialogar

PPTX
Aysun Karatas MedicReS World Congress 2015
byMedicReS
 
PDF
Cancer Research Activity Report 2012 By Cancer Council New South Wales
byCancer Council NSW
 
PDF
2011 AACR CancerProgressReport_text_web
byOregon Health & Science University
 
PPTX
Big Data OncoAnalytics Architecture
byPhilippe Julio
 
PDF
The 10 Most Impactful Leaders in Life Science.pdf
byTHECIOWORLD
 
PDF
Acibadem City Clinic Cancer Center
byTsvetelina Hristova
 
PPTX
Big Databases and Outcome Research - Opportunities and Challenges for Radiati...
byAndre Dekker
 
PDF
CHI-and-Onyx-Pharmaceuticals-Oncology-Report
byWill Zasadny
 
PPTX
Julio E. Celis-Investigar, educar, dialogar
byFundación Ramón Areces
 
PPTX
Personalized Cancer Care
byPaige W
 
PDF
NeoGenomics Company Overview Presentation | 07-27-2015
byNeoGenomics Laboratory | Cancer Diagnostics
 
PPTX
Spain Startup Pitches 2
bySpainStartUp
 
PDF
HealthBIO 2021_Cancer I/O Translating immuno-oncology into health actions_Jer...
byBusiness Turku
 
PDF
NeoGenomics Company Overview Presentation 03/06/2015
byNeoGenomics Laboratory | Cancer Diagnostics
 
PDF
NeoGenomics Company Overview Presentation 2016 03 14
byNeoGenomics Laboratory | Cancer Diagnostics
 
PPTX
Cancer 2014: Why do we need a focus on value?
byPharmacy @ Institut Kanser Negara
 
PPT
Genentech
byMarianna Malaspina
 
PDF
MN Cancer Summit - February 28, 2019 - Mid-Day Plenary Speaker Presentation
byEmil Lou, M.D., Ph.D, FACP
 
PDF
Company Overview Presentation
byJeanCharles Dervieux
 
PDF
Neurochemistry 2019 Brochure
byPRADEEPKUMARK26
 
Aysun Karatas MedicReS World Congress 2015
byMedicReS
 
Cancer Research Activity Report 2012 By Cancer Council New South Wales
byCancer Council NSW
 
2011 AACR CancerProgressReport_text_web
byOregon Health & Science University
 
Big Data OncoAnalytics Architecture
byPhilippe Julio
 
The 10 Most Impactful Leaders in Life Science.pdf
byTHECIOWORLD
 
Acibadem City Clinic Cancer Center
byTsvetelina Hristova
 
Big Databases and Outcome Research - Opportunities and Challenges for Radiati...
byAndre Dekker
 
CHI-and-Onyx-Pharmaceuticals-Oncology-Report
byWill Zasadny
 
Julio E. Celis-Investigar, educar, dialogar
byFundación Ramón Areces
 
Personalized Cancer Care
byPaige W
 
NeoGenomics Company Overview Presentation | 07-27-2015
byNeoGenomics Laboratory | Cancer Diagnostics
 
Spain Startup Pitches 2
bySpainStartUp
 
HealthBIO 2021_Cancer I/O Translating immuno-oncology into health actions_Jer...
byBusiness Turku
 
NeoGenomics Company Overview Presentation 03/06/2015
byNeoGenomics Laboratory | Cancer Diagnostics
 
NeoGenomics Company Overview Presentation 2016 03 14
byNeoGenomics Laboratory | Cancer Diagnostics
 
Cancer 2014: Why do we need a focus on value?
byPharmacy @ Institut Kanser Negara
 
Genentech
byMarianna Malaspina
 
MN Cancer Summit - February 28, 2019 - Mid-Day Plenary Speaker Presentation
byEmil Lou, M.D., Ph.D, FACP
 
Company Overview Presentation
byJeanCharles Dervieux
 
Neurochemistry 2019 Brochure
byPRADEEPKUMARK26
 

More from Fundación Ramón Areces

PPTX
Jordi Torren - Coordinador del proyecto ESVAC. Agencia Europea de Medicamento...
byFundación Ramón Areces
 
PDF
Dominique L. Monnet Director del programa ARHAI (Antimicrobial Resistance an...
byFundación Ramón Areces
 
PPTX
Antonio Cabrales -University College of London.
byFundación Ramón Areces
 
PPTX
Teresa Puig - Institut de Ciència de Materials de Barcelona, ICMAB-CSIC, Espa...
byFundación Ramón Areces
 
PDF
Elena Bascones - Instituto de Ciencia de Materiales de Madrid (ICMM-CSIC), Es...
byFundación Ramón Areces
 
PDF
Jonathan D. Ostry - Fondo Monetario Internacional (FMI).
byFundación Ramón Areces
 
PDF
Martín Uribe - Universidad de Columbia.
byFundación Ramón Areces
 
PPTX
Thomas S. Robertson - The Wharton School.
byFundación Ramón Areces
 
PPTX
Diana Robertson - The Wharton School.
byFundación Ramón Areces
 
PPTX
Juan Carlos López-Gutiérrez - Unidad de Anomalías Vasculares, Hospital Unive...
byFundación Ramón Areces
 
PPTX
Víctor Martínez-Glez. - Instituto de Genética Médica y Molecular (INGEMM). I...
byFundación Ramón Areces
 
PPT
Rudolf Happle - Dermatología, University of Freiburg Medical Center, Freiburg...
byFundación Ramón Areces
 
PDF
Rafael Doménech - Responsable de Análisis Macroeconómico, BBVA Research.
byFundación Ramón Areces
 
PPTX
Diego Valero - Presidente del Grupo Novaster.
byFundación Ramón Areces
 
PPTX
Mercedes Ayuso - Universitat de Barcelona.
byFundación Ramón Areces
 
PPTX
Nicholas Barr - Profesor de Economía Pública, London School of Economics.
byFundación Ramón Areces
 
PPTX
Julia Campa - The Open University.
byFundación Ramón Areces
 
PDF
Juan Manuel Sarasua - Comunicador y periodista científico.
byFundación Ramón Areces
 
PPTX
Marta Olivares - Investigadora Postdoctoral en Université catholique de Louva...
byFundación Ramón Areces
 
PPTX
Frederic Lluis - Investigador principal en KU Leuven.
byFundación Ramón Areces
 
Jordi Torren - Coordinador del proyecto ESVAC. Agencia Europea de Medicamento...
byFundación Ramón Areces
 
Dominique L. Monnet Director del programa ARHAI (Antimicrobial Resistance an...
byFundación Ramón Areces
 
Antonio Cabrales -University College of London.
byFundación Ramón Areces
 
Teresa Puig - Institut de Ciència de Materials de Barcelona, ICMAB-CSIC, Espa...
byFundación Ramón Areces
 
Elena Bascones - Instituto de Ciencia de Materiales de Madrid (ICMM-CSIC), Es...
byFundación Ramón Areces
 
Jonathan D. Ostry - Fondo Monetario Internacional (FMI).
byFundación Ramón Areces
 
Martín Uribe - Universidad de Columbia.
byFundación Ramón Areces
 
Thomas S. Robertson - The Wharton School.
byFundación Ramón Areces
 
Diana Robertson - The Wharton School.
byFundación Ramón Areces
 
Juan Carlos López-Gutiérrez - Unidad de Anomalías Vasculares, Hospital Unive...
byFundación Ramón Areces
 
Víctor Martínez-Glez. - Instituto de Genética Médica y Molecular (INGEMM). I...
byFundación Ramón Areces
 
Rudolf Happle - Dermatología, University of Freiburg Medical Center, Freiburg...
byFundación Ramón Areces
 
Rafael Doménech - Responsable de Análisis Macroeconómico, BBVA Research.
byFundación Ramón Areces
 
Diego Valero - Presidente del Grupo Novaster.
byFundación Ramón Areces
 
Mercedes Ayuso - Universitat de Barcelona.
byFundación Ramón Areces
 
Nicholas Barr - Profesor de Economía Pública, London School of Economics.
byFundación Ramón Areces
 
Julia Campa - The Open University.
byFundación Ramón Areces
 
Juan Manuel Sarasua - Comunicador y periodista científico.
byFundación Ramón Areces
 
Marta Olivares - Investigadora Postdoctoral en Université catholique de Louva...
byFundación Ramón Areces
 
Frederic Lluis - Investigador principal en KU Leuven.
byFundación Ramón Areces
 

Recently uploaded

PDF
Detection of an NH3 Absorption Band at 2.2μm on Europa
bySérgio Sacani
 
PPTX
OECD 204 (Acute Dermal Toxicity) .pptx
byManjari36
 
PDF
Gas-depleted planet formation occurred in the four-planetsystem around the re...
bySérgio Sacani
 
PDF
Nuclear Magnetic Resonance Hindi Medium Notes PDF Download - World of Wisdom.pdf
byWorld of Wisdom
 
PDF
Probiotic bacteria and their importance in aquaculture.pdf
byChinaSamy1
 
PPTX
1. BEHAVIOURAL SCIENCE An Introduction for Medical Students.pptx
bygbadamosiayomide
 
PDF
ExomoonsearchwithVLTI/GRAVITYaroundthesubstellar companionHD206893B
bySérgio Sacani
 
PDF
Surface Chemistry ( पृष्ठ रसायन ) - Notes PDF - Irfanullah Mehar - JJ Sir Che...
byWorld of Wisdom
 
PPT
Electric Fields and capacitance AQA A-level Physics
bybensonr1993
 
PPTX
ELectromagnitism.pptx ELectromagnitism.p
byLeahJaneMalinao1
 
PPTX
Vericiguat in Chronic Coronary Syndrome PPT
byservierevolmed
 
PPTX
VIRULENCE FACTOR OF BACTERIA: STRUCTURAL ELEMENT, ENZYMES, TOXINS...
byBIOSPHERE OF KNOWLEDGE
 
PPTX
Grade 9 - Science Fourth Quarter Physics
byModezaPonje
 
PPTX
Anaerobic respiration (Fermentation, Types, Pasteur effect, Warburg effect, R...
byRashmiMG2
 
PDF
Possible identification of the Luna 9 Moon landing site using a novel machine...
bySérgio Sacani
 
PDF
Solid Waste Management (SWM) _2026003456
byvanitha7273
 
PDF
Age of exploration - ppt presentation_EAPT
byericaangelatoledo06
 
PDF
The Crab Nebula Revisited Using HST/WFC3
bySérgio Sacani
 
PPTX
History_Taking_and_Physical_Examination_of_Cardiovascular_System.pptx
byalirazzaghi137900
 
PPTX
Cell cycle ( mitosis and meiosis)Msc.pptx
byPallabiBehera9
 
Detection of an NH3 Absorption Band at 2.2μm on Europa
bySérgio Sacani
 
OECD 204 (Acute Dermal Toxicity) .pptx
byManjari36
 
Gas-depleted planet formation occurred in the four-planetsystem around the re...
bySérgio Sacani
 
Nuclear Magnetic Resonance Hindi Medium Notes PDF Download - World of Wisdom.pdf
byWorld of Wisdom
 
Probiotic bacteria and their importance in aquaculture.pdf
byChinaSamy1
 
1. BEHAVIOURAL SCIENCE An Introduction for Medical Students.pptx
bygbadamosiayomide
 
ExomoonsearchwithVLTI/GRAVITYaroundthesubstellar companionHD206893B
bySérgio Sacani
 
Surface Chemistry ( पृष्ठ रसायन ) - Notes PDF - Irfanullah Mehar - JJ Sir Che...
byWorld of Wisdom
 
Electric Fields and capacitance AQA A-level Physics
bybensonr1993
 
ELectromagnitism.pptx ELectromagnitism.p
byLeahJaneMalinao1
 
Vericiguat in Chronic Coronary Syndrome PPT
byservierevolmed
 
VIRULENCE FACTOR OF BACTERIA: STRUCTURAL ELEMENT, ENZYMES, TOXINS...
byBIOSPHERE OF KNOWLEDGE
 
Grade 9 - Science Fourth Quarter Physics
byModezaPonje
 
Anaerobic respiration (Fermentation, Types, Pasteur effect, Warburg effect, R...
byRashmiMG2
 
Possible identification of the Luna 9 Moon landing site using a novel machine...
bySérgio Sacani
 
Solid Waste Management (SWM) _2026003456
byvanitha7273
 
Age of exploration - ppt presentation_EAPT
byericaangelatoledo06
 
The Crab Nebula Revisited Using HST/WFC3
bySérgio Sacani
 
History_Taking_and_Physical_Examination_of_Cardiovascular_System.pptx
byalirazzaghi137900
 
Cell cycle ( mitosis and meiosis)Msc.pptx
byPallabiBehera9
 

María Blasco-Investigar, educar, dialogar

  • 1.
    Spanish National CancerResearch Centre (CNIO) Going beyond “excellence”
  • 2.
    A bit ofhistory…  The Spanish National Cancer Research Centre (CNIO) was conceived by the Spanish Government at the end of the 90’s as a part of a long term Strategic Plan to endow Spain with a series of excellence research centres (CNIO, CNIC, etc)  CNIO is managed by a Public Foundation currently belonging to the Spanish Ministry of Economy and Competitivity (MINECO)  The CNIO has independence to manage its funds and human resources under a criterium of scientific excellence (External Scientific Advisory Board)  CNIO personnel enjoys work contracts identical to those of the employees of private companies  CNIO has control of its budget, including funds provided by the Ministry  The CNIO Director reports directly to the Board of Trustees, presided by the Secretary of State for Research, currently Ms. Carmen Vela  Main features of CNIO’s administrative system include:
  • 3.
    CNIO External AdvisoryBoard (2016) Mariann Bienz (Chair) Medical Research Council, Cambridge, UK Joan Massagué Memorial Sloan Kettering Cancer Center, New York, USA Angela Nieto Instituto de Neurociencias, Alicante, Spain Lauri Altoonen Biomedicum, Univ. of Helsinski, Finland Genevieve Almouzni Institute Curie, Paris, France Sara Courtneidge Oregon Health & Science University, Portland, USA John Diffley CRUK London Research Institute, Hertfordshire, UK Denise Galloway Fred Hutchinson Cancer Research Center, Seattle, USA Scott Lowe Memorial Sloan Kettering Cancer Center, New York, USA Janet Thornton European Bioinformatics Institute, Hinxton, UK Michael Bishop Hooper Research Foundation, San Francisco, USA Ada Jonah Weizmann Institute of Science, Rehovot, Israel José Costa Yale Comprehensive Cancer Center, New Haven, USA Karen Vousden The Beatson Institute for Cancer Research, Glasgow, UK Alfred Wittinghofer Max Plank Institute for Molecular Physiology, Dortmund, Germany Josep Tabernero Director Oncology Institute, Vall d’Hebron Hospital, Barcelona, Spain
  • 4.
    14% non-spanish Group LeadersStaff Scientists Lab techs 22% non-spanish 11% non-spanish Post-doctorals PhD students 49% non-spanish 41% non-spanish International Environment
  • 5.
  • 6.
    Research Organization (2016) BasicResearch Cancer Cell Biology 4 Research Groups: 2 senior + 3 junior Molecular Oncology 10 Research Groups: 7 senior + 3 new Junior Groups in 2016 Structural Biology and Biocomputing 3 Research Groups: 1 senior + 2 junior 3 Support Units + 1 new Unit on Text Mining in 2016 E. WAGNER M. SERRANO A. VALENCIA (Vice-Director)
  • 7.
    Translational Research Human CancerGenetics 4 Research Groups: 4 senior 2 Support Units Clinical Research (CNIO-Hospitals) 3 Clinical Research Units: 1 senior + 2 junior 2 Support Units 2 new CNIO-H12O Clinical Research Units in 2015 Biotechnology 8 Support Units Experimental Therapeutics 2 sections (Biology & Chemistry) 2 Eli-Lilly labs Technology Transfer J. BENITEZ M. HIDALGO (Vice-Director hasta Dec 2015) O. FERNANDEZ-CAPETILLO (Vice-Director Director de Innovación) F. PELAEZ J. PASTOR Research Organization II (2016) A. SANZ
  • 8.
    CNIO Excellence (rankings, papers,etc) Spanish National Cancer Research Centre (CNIO)
  • 9.
    Total number ofpublications 0 50 100 150 200 250 300 Totalnumberofscientificpublications Senior author from CNIO CNIO co-authorship
  • 10.
  • 11.
    International Ranking 2015(cancer centers) (out of 4840 institutions (99 Spain) Scimago July 2010-2015) Excellence with Leadership CNIO Position in the International Ranking Cancer Centers Rank Cancer Research Centers Country Ewl %Ewl: Excelence with Leadership: The amount (in %) of an institution’s scientific output that is included into the set of the 10% of the most cited papers in their respective scientific fields in which the institution is the main contributor. This is a size- independent indicator.
  • 12.
    Parameter Q1 International Ranking2015 (cancer centers) (out of 4840 institutions (99 Spain) Scimago July 2010-2015) CNIO Position in the International Ranking Cancer Centers Rank Cancer Research Centers Country Q1 Q1: High Quality Publications: Ratio of publications that an institution publishes in the most influential scholarly journals of the world, those ranked in the first quartile (25%) in their categories as ordered by SCImago Journal Rank (SJRII) indicator. This is a size-independent indicator.
  • 13.
    Scientific productivity accordingto Nature Index AC: Total number of papers from June 1st, 2014, to May 31st, 2015 FC: Fractional count (considering the % of CNIO authors and number of institutions in each paper) WFC: Weighted fractional count in which some fields of physics is down weighted Nature Index tracks data from the publications issued in a selection of 68 high quality journals compiled by the Nature Publishing Group in collaboration with Digital Science
  • 14.
    Ranking of Spanishinstitutions according to Nature Index The table includes top Spanish institutions in the field of life sciences, ranked by their FC
  • 15.
  • 16.
    Associated Hospitals Oncologists onboard Spanish National Cancer Research Centre (CNIO)
  • 17.
    Red de EnsayosClínicos CNIO 2015 Clinical Trial Network (collaborations ad hoc) Associated Clinical Units # Hospital HM - Hospital de Madrid (since 2008) # Hospital Fuenlabrada (since 2009) # Hospital Ramón y Cajal (since 2012) # Hospital La Paz (since 2012) # Fundación Jiménez Díaz (since 2012) # Hospital Niño Jesús (since 2013) # Hosp. Regional y Virgen de la Victoria Málaga (since 2014) # Hospital 12 de Octubre (since 2015) # Hospital Clínico San Carlos (since 2015) # Hospital Quirón (since 2016) M. HIDALGO Programme Director CNIO M.A. QUINTELA (CNIO) D. OLMOS (CNIO) L. MORENO (CNIO) J. MARTÍNEZ (CNIO-H12O) L. PAZ-ARES (CNIO-H12O)
  • 18.
    Personalized cancer treatmentplatform Human tumour implant in mice (xenograft) ‘AVATAR’ mice Bioinformatic Analysis Data handling & integration Testing of candidate drugs in Avatar mice Therapeutic decision (personalised treatment) Datacollection # Molecular data # Clinical data # Biological data # Pharmacol. data # Epidemiologic data # Databases & Publ. Extraction of clinically ‘useful’ information
  • 19.
    Hidalgo et al,Can Dis 2014 Avatars recapitulate the patient´s tumor
  • 20.
    NGS: next generationsequencing positive: genetic councelling negative: more research candidates for NGS new genes We discover new familial cancer genes
  • 21.
    We read allexome Rapid translation of results
  • 22.
  • 23.
    Drug development atCNIO Joaquin Pastor, Director of Experimental Therapeutics Program at CNIO
  • 24.
    Drug discovery atCNIO: Our mission “Our mission is to serve as a bridge between basic research and potential therapeutic applications through the discovery and development of innovative drug candidates for clinical development”
  • 25.
    VIB: Model forExternal Collaborations Currently under CNIO Internal development Drug discovery at CNIO: Our pipeline
  • 26.
    Development of ATRinhibitors IN COLLABORATION WITH EXPERIMENTAL THERAPEUTICS PROGRAM O. F-CAPETILLO
  • 27.
    10 Gy +ATRi mM ATMp Chk1p TOLEDO ET AL NSMB (2011) Clinical Trials 2016 2013 ETP CNIO Development of ATR inhibitors Income millestones 2013- 2015: 900.000 euros Next millestone: 1.500.000 euros
  • 28.
    4 Spanish Centersare registered… “ETP-CNIO” is Unique in Spanish Public Research Institutions meeting the criteria of “pharma”/academic experience, integrated capabilities and a proven record of achievements in academic drug discovery. Drug discovery at CNIO: part of a network
  • 29.
    Income from partnering 2015: Significant increase ( 2 X ) in the number of industrial collaborators (from 10 to 20) . (new agreements wit Boehringer Ingelheim, Merck KaaG, Daiichi Sankyo…) Significant increase in funding for fundamental research projects ( preclinical research)  4.5 M. € secured for collaborative research Significant increase in funding for fundamental research projects ( preclinical ) 1.425773 1.706681 2.675406 2.535579 4.715486 4.48672988 0 0.5 1 1.5 2 2.5 3 3.5 4 4.5 5 2010 2011 2012 2013 2014 2015 (Dic) Millions Collaborative Research with partnering
  • 30.
  • 31.
    CNIO Royalties –commercialization -  CNIO Intelectual Property Portfolio  60 patents (2007-2015)  14 (23%) have been licenced  In 2015, 1 new priority patent application (ETP)  24 commertial reagents (antibodies & chemical compounds)  2014 commertialization  25 technologies in exploitation: 24 marketed; 1 (ATRi) in development  Net royalty (2014): 780.840 €  Income from royalties contributes to the sostenability of the centre, to support research in the research groups that generate the invention and to recognize the Inventors. Spin Offs Chemical Matter Biological Material
  • 32.
    CNIO Inventors (>10%of CNIO personnel)  CNIO is commited to recognize its Inventors, thorugh a royalty distribution policy  More than 40 scientist have contributed to the development of the commertialized technologies. (aprox. 10% of CNIO personnel).  CNIO Inventors belong to all scientific programs. Molecular Oncology, Biotechnology and Experimental Therapeutic being the main contributors. 1 2 3 Inventors Research Groups CNIO Institution Inventors per Scientific Programme Royalty Distribution
  • 33.
    Training researches inmanagement and bussines administration In collaboration with IE business School  23 CNIO scientist have followed the training  Building skills & attitudes, Expanding CNIO Network. Fostering Innovation Culture
  • 34.
    Update training & conferences PhDs,postdocs, seminars, meetings…. Spanish National Cancer Research Centre (CNIO)
  • 35.
  • 36.
    Training Programs (2014-2015) PhDFellowships associated to Severo Ochoa Program “La Caixa” – Severo Ochoa International PhD Program Posdoctoral Program for scientists from UK or USA (Banco Santander Foundation) Training Program on Molecular Pathology for medical residents Training Program on Familial Cancer for MIR, BIR and FIR CNIO Onco-MIR Rotation Program for MIR residents (Celgene) CNInnOtrain Program IE Business School (Banco Santander Foundation) Laboratory Training Program for Undergraduate and Postgraduate Students Training Program for Vocational Students (Laboratory Technicians) Master in Therapeutical Targets, Research and Development (Alcalá de Henares University) Diploma on Translational Research applied to Personalized Oncology. Master in Clinical Research Applied to Oncology (San Pablo-CEU University) Master in Molecular Oncology (Centro de Estudios Biosanitarios) Postgraduate Program in Biochemistry, Molecular Biology, Biomedicine and Biotechnology (Autónoma University of Madrid) Program for visiting scientists at CNIO (Jesus Serra Foundation)
  • 37.
    Distinguished Seminars byOncology Leaders
  • 38.
    Distinguished Seminars withthe French Embassy Shahragim Tajbakhsh Instituto Pasteur 7 Noviembre 2014 Jean-Pierre Changeux Instituto Pasteur Paris, France 4 Noviembre 2014 Emmanuel Barillot Instituto Curie 13 Junio 2014
  • 39.
    We organize internationalconferences  CNIO Frontiers Meetings (2-3 year)  Nature-CNIO Symposia (2007, 2010, 2013)  Co-organizing with International Associations (p.ej. ESO)
  • 40.
    2016 Canceromatics III: Tumourheterogeneity Organizers: Fatima Al-Shahrour (CNIO, Madrid) Núria Malats (CNIO, Madrid) Alfonso Valencia (CNIO, Madrid) Chris Sander (MSKCC,USA) Proposed date: 13-16 Nov, 27-30 2017 Molecular Chaperones in Cancer Organizers: Nabil Djouder (CNIO, Madrid) Wilhelm Krek (ETH, Zurich) Paul Workman (ICR, London) Helena Yang (Cancer Cell Editor) Date: 2-4 May Malignancies in the Central Nervous System: Unknown Biologies towards Therapeutic Applications Organizers: Manuel Valiente (CNIO, Madrid) Massimo Squatrito (CNIO, Madrid) Richard Gilbertson (Cancer Research UK Cambridge Centre) Lisa Hutchinson(Nature Reviews Clinical Oncology Editor) Date: 19-21 Oct CNIO Frontiers Meetings 2016 and 2017
  • 41.
    Patrick Sung Yale UniversitySchool of Medicine, USA (Chromosome Dynamics Group) Chaitanya R. Divgi Columbia University, NY Presbyterian Hospital, USA (Seve-Ballesteros Foundation Brain Tumour Group ) Marcin Nowotny International Institute of Molecular and Cell Biology, Poland (Structural Bases of Genome Integrity Group ) Sabaticals “Jesús Serra” 2015
  • 42.
    New logo Womenin Science @ CNIO Office
  • 43.
    Seminars of theWomen in Science (WISE) office 2016 María Teresa Fernández de la Vega. President Fundación Mujeres por Africa, Madrid, Spain Edurne Pasaban. Mountaineer, Tolosa, Spain In Her Own Voice: MIT's Earliest Women Scientists. Margery Resnick. Massachusetts Institute of Technology, Cambridge, US and International Institute in Madrid, Spain Woman and Technology: a positive story. María Concepción Ferreras. You Tube, Head of Partnerships, Southern Europe and Russia 2015 Women in Business and Science : two parallel paths. Natalia González- Valdés. Corporate Communications and CSR (Corporate Social Responsibility) Director of L'Oreal Spain Women at the top: Making it happen. María del Mar Martínez. Director at McKinsey's Madrid Office, Spain My life with phage ø29. Margarita Salas Falgueras. CBMSO, Madrid, Spain A professional career with a gender perspective. Maria Carmen Vela Olmo. Secretariat of State of Research, Development and Innovation, Ministry of Economy and Competitiveness, Madrid, Spain Sex, Science and Society: a triangle that matters? Flora de Pablo. CSIC, Madrid, Spain 10/05 08/03 19/01 12/01 24/11 09/06 14/04 10/03 17/02
  • 44.
    Communication & outreach: Newspapers, TV, social networks… Spanish National Cancer Research Centre (CNIO)
  • 45.
    Communication CNIO appearances inprinted & digital media (up to 30th November 2015) 0 500 1000 1500 2000 2500 3000 Jan-Mar Apr-Jun Jul-Sep Oct-Dec Total 89 118 87 98 392 98 250 220 193 761 195 378 342 438 1353 387 547 603 760 2297 587 629 685 624 2525 2011 2012 2013 2014 2015 (up to 30 Nov)
  • 46.
    International presence ofCNIO press releases (from March 2012 to 30th November 2015) Press Releases Published: 110 Total visits: 308,514 Communication Average/PR: 2,805 Average/month: 6,855 Top 15 Press Releases
  • 47.
    Communication TV and radiobroadcasts [Colombia]
  • 48.
  • 49.
  • 50.
    Public engagement -Events Science’s Week Initiative organised by Madri+d. The attendants learned more about the CNIO facilities, enjoyed a guided tour in some of the laboratories and talked with our researchers about the scientific career and the work In the Centre. Attendants: 50 people European Researchers’ Night Activity organised by Madri+d. Children and adults had the opportunity to learn more on the CNIO cancer research. They also extracted DNA from a tomato and took part in a ‘speed dating’ session with the 40 young researchers who participated in the activity. Attendants: 200 people 25/09/2015 05/11/2015
  • 51.
  • 52.
    Launched in February2015 for the initiative “CNIO Friends” Communication From February 15, 2015, to May 12, 2016: 31,026 followers Reach: 50,767.231 users * 239,664 ‘likes’ 16,676 comments 66,555 shares * Number of people who received contents from the page Interaction: 73% * * Number of interactions per followers
  • 53.
    Internet Day Award– Best Facebook Page 2016 Communication
  • 54.
    Shown and airedin:CNIO Friends appearances: Print and digital media: 87 Radio: 18 TV: 13 Video “Become a Friend of CNIO” Total views in Youtube: 22,844 Video by Amparo Garrido
  • 55.
    0 € 10.000 € 20.000€ 30.000 € 40.000 € 50.000 € 60.000 € 70.000 € 80.000 € 90.000 € 100.000 € 2011 2012 2013 2104 2015 2016 Donations CNIO Friends Donations before the launch of CNIO Friends Evolution of donations at CNIO * * The initiative “CNIO Friends” was launched in November 2014 (until May 23)
  • 56.
    CNIO Friends (May23, 2016): 657 donors 598 8 Sponsors Benefactors Friends 51
  • 57.
    Amigos del CNIO:primera empresa Patrocinadora
  • 58.
    New CNIO Friends + Researchon children’s cancers Recreational areas in hospitals for children with cancer
  • 59.
    • ERC Bridge:An endowment based on the legacy from D. Miguel Martín (ca. 400,000€) to support the Groups of Excellence of the CNIO  Other legacies can be added in the future • Goal: to provide financial support to Groups in the the process of renewing their ERC Grants. • Eligibility criteria: Groups holding an ERC Grant (Starting, Consolidator or Advanced), which apply again but do not get the new one right after • Procedure:  Groups will place a request to CNIO for this support, indicating the amount requested and intended destination of the funds  Maximum amount granted: 100,000€ for Senior Groups; 50,000€ for Junior Groups  Maximum time: 1 year o The amount would be reduced proportionally if the renewal of the grant is obtained before the end of this 1-year period. Creation of the “ERC Bridge Endowment”
  • 60.
    “Constantes y Vitales”:La Sexta + Fundación AXA  >6,000 participants; 650,000 Km  100,000 euros to fund the research of the Microenvironment and Metastasis Group (Héctor Peinado) at CNIO  Challenge: to turn Kms into one year of cancer research
  • 61.
    0 € 50.000 € 100.000€ 150.000 € 200.000 € 250.000 € 300.000 € 350.000 € 400.000 € 2011 2012 2013 2104 2015 2016 Donations before the launch of CNIO Friends Donations CNIO Friends ATRESMEDIA Legacies Evolution of donations at CNIO * (until May 23) * The initiative “CNIO Friends” was launched in November 2014
  • 62.
    CNIO Friends Fund CNIOFRIENDS POSTDOCTORAL FELLOWSHIPS Duration: 2 years Starting 2016
  • 63.
    Our view ofthe CNIO Research Innovation Solutions $ Training Communication Phylantropy $ Education WIS E WIS E Dean´s Offic e CNI O Personnel Unions
  • 64.
    Negotiation of theCollective Agreement Excerpt of the Agreement signed by the Fundación CNIO Carlos III with the Works Council on December 20, 2013: “…..it is agreed to initiate the negotiations on the 1st of February of 2014 to ellaborate a Collective Agreement for all the workers of the Centre”. Negotiating Table Activities 2014 - A first draft of the Collective Agreement is elaborated for discussion Activities 2015 - January 21: kick off of the negotiation and discussions on the draft - July 27: after 18 meetings between the parties, a first agreed version is reached that is communicated to all the employees - Sept-Nov: last changes are incorporated to present a final version to the meeting of the Board of Trustees in December Agreements already reached - June 23: The Board of Trustees approves the application of the new timetable based on 37.5 hours per week in an unbroken day schedule (Art. 24) - July 24: The application of the new policy on the compensation of extra hours beyond the regular time schedule is approved (Art. 25) - October 28: The Comisión Delegada approves the consideration of the 24th and 31st of December as non-working days (Art. 27) Director Managing Director Dir. Biotechnology Programme Dir. Experimental Therapeutics Prog. Dir. Administration and Finances Dir. Personnel Chair of the Works Council 5 members representing the different sections of the Council: 2 members of CCOO 2 members of UGT 1 member of “Integrando CNIO” On behalf of the CNIO On behalf of the Works Council
  • 65.
    Our view ofthe CNIO Research Innovation Solutions $ WIS E WIS E Dean´s Offic e CNI O Personnel Unions Training Communication Phylantropy $ Education
  • 66.
    Spanish National CancerResearch Centre (CNIO) After substantial operative deficit during (2009-2012),CNIO accounts are now balanced: 2012: -4.849.000 € 2013: +1.016.000 € 2014: +488.000 € 2015: +100.000 € 2016: aprox. +100.000 € (estimation) We are, however, returning the ETP loans (2009-2011) to the Government (~4 M € per year) and this represents a stress to our savings
  • 67.
    Looking ahead: CNIO 2015-2018 SpanishNational Cancer Research Centre (CNIO)
  • 68.
    Spanish National CancerResearch Centre (CNIO) Groups 2015-2018 Five Junior Groups (Pérez-Moreno, Djouder, Quintela, Ramón-Maiques, and Lietha) will finish their 5+3 stay at the CNIO. Two Junior Groups (Squatrito and Olmos) will have their 5- year evaluation for a 3-extension at CNIO). Three new Junior Groups (Peinado, Valiente, Efeyan) would be at their mid-term period at CNIO. Recruitment of new Groups (Structural Biology; Immune System; Microbiota…others?).
  • 69.
    Spanish National CancerResearch Centre (CNIO) Challenges Renew the Severo Ochoa Excellence Acreditation (2016- 2020) (1 million €). Increase public funding (Government + Competitive). Increase contracts with Industry (ETP + Groups). Increase institutional and individual phylantropy. Recover flexibility: hiring, salaries (productivity)….
  • 70.
    Highlighted appearances inprinted & digital media Communication
  • 71.
    Communication Social media Launched inJune 2009 70 videos 172 subscribers Total views: 35,963
  • 73.
    10 Gy +ATRi mM ATMp Chk1p Development of ATR inhibitors TOLEDO ET AL NSMB (2011) Sent to > 70 laboratories around the world We provided the Synthesis protocol as Supp Information Towards the Clinic TOLEDO ET AL NAT STRUCT MOL BIOL (2008) 2013 ETP CNIO Income 2013-2015: 900.000 euros
  • 74.
  • 75.
    Carbo/PEM + Demcizumab Ph1b FL-NSCLC (IIIB/ IV) • Carbo:AUC 6 Q3W x 6 • PEM: 500 mg/m2 Q3W x 6 • DEM: 2.5, 5mg/kg Q3W and 7.5mg/kg Q3W x4 Demcizumab: inhibidor de Notch en NSCLC fase 1
  • 76.
    Demcizumab: First-Line NSCLCStudy RECIST Waterfall Plot Partial Response 9/28 (39%) Stable Disease 1/28 (48%) Progress Dis. 3/28 (13%)
  • 77.
    Collaborations with BigPharma (Roche) 3 projects funded (2013- 2015) A total of 520.000 euros
  • 78.
    H12O-CNIO Clinical ResearchUnits since 2015 Joaquín Martínez Luís Paz-Ares
  • 79.
    Tumor detection by PET/CT 15 days afterdetection No treatment Mouse with a lung tumor Untreated mouse Mouse with a lung tumor Treated with Notch inhibitor Tumor detection by PET/CT 15 days After treatment Accelerate translation from basic research to patients Notch: A new target for lung and pancreas cancer Clinical Trial with anti-Notch in pancreas And lung cancer (ONCOMED Anti-DLL4) Maraver et al. Cancer Cell, 2012 Manuel Serrano Tumor Suppression Group CNIO
  • 80.
  • 81.
    0 10 2030 40 0 200 400 600 800 1000 1200 1400 Control mAb Gemcitabine (30 mg/kg) Gem (10 mg/kg) +Abrx (30 mg/kg) Anti-DLL4 + Gem Anti-DLL4 + Gem/Abrx Days Post Treatment TumorVolume,mm3 • Patient progressed on treatment, day 11 (anti-DLL4, 2.5 mg/kg q4w + gemcitabine) • Patient derived tumor shows increased sensitivity to gem/Abraxane vs. gem alone • Combination activity observed with anti-DLL4 + gem/Abraxane, but not with anti-DLL4 + gem 0 10 20 30 40 0 100 200 300 Gem (10 mg/kg) +Abrx (30 mg/kg) Anti-DLL4 + Gem/Abrx Anti-DLL4/VEGF + Gem/Abrx Days Post Treatment TumorVolume,mm3Gem/Abraxane vs. Gem/Abrx + Anti-DLL4; P = 0.04 Discovery of new drug combinations
  • 82.